Trial Profile
A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA 51) Following Completion of Prescribed Chemotherapy or Trastuzumab for TXN2-3M0 or Metastatic Breast Cancer With No Evidence of Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs IMT 1012 (Primary) ; Breast cancer vaccine; Granulocyte macrophage colony stimulating factor; Montanide ISA-51
- Indications Advanced breast cancer
- Focus Adverse reactions
- 29 Mar 2011 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
- 29 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.